Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $940000.0.

  • Assembly Biosciences' Change in Account Payables rose 7603.0% to $940000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $348000.0, marking a year-over-year decrease of 3968.8%. This contributed to the annual value of $124000.0 for FY2024, which is 10610.24% up from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Change in Account Payables is $940000.0, which was up 7603.0% from -$132000.0 recorded in Q2 2025.
  • Assembly Biosciences' Change in Account Payables' 5-year high stood at $1.0 million during Q2 2022, with a 5-year trough of -$1.3 million in Q1 2023.
  • For the 5-year period, Assembly Biosciences' Change in Account Payables averaged around -$153421.1, with its median value being -$146000.0 (2023).
  • Its Change in Account Payables has fluctuated over the past 5 years, first plummeted by 58671.33% in 2021, then skyrocketed by 167741.94% in 2022.
  • Assembly Biosciences' Change in Account Payables (Quarter) stood at $31000.0 in 2021, then skyrocketed by 1677.42% to $551000.0 in 2022, then crashed by 153.9% to -$297000.0 in 2023, then plummeted by 152.53% to -$750000.0 in 2024, then skyrocketed by 225.33% to $940000.0 in 2025.
  • Its Change in Account Payables stands at $940000.0 for Q3 2025, versus -$132000.0 for Q2 2025 and $290000.0 for Q1 2025.